Durect Corp (NAS:DRRX)
$ 0.95 -0.0181 (-1.87%) Market Cap: 29.49 Mil Enterprise Value: 32.85 Mil PE Ratio: 0 PB Ratio: 24.36 GF Score: 56/100

Q3 2023 DURECT Corp Earnings Call Transcript

Nov 13, 2023 / 09:30PM GMT
Release Date Price: $0.5258 (-0.87%)
Operator

Good afternoon, everyone, and welcome to the DURECT Corporation third-quarter earnings conference call. All participants will be in a listen-only mode. (Operator Instructions) After today's presentation, there will be an opportunity to ask questions. (Operator Instructions) Please also note today's event is being recorded. And at this time, I'd like to turn the floor over to Tim Papp, Chief Financial Officer. Please go ahead.

Tim Papp
DURECT Corporation - CFO

Thank you. Good afternoon and welcome to DURECT Corporation's third-quarter 2023 earnings conference call. Before we begin, I would like to remind everyone of our forward-looking statements. During the course of this call, we will make forward-looking statements regarding the results and clinical data from the AHFIRM trial, development plans for larsucosterol, expected product benefits, market potential, regulatory plans, potential regulatory approval, and the company's financial projections.

These forward-looking statements involve risks and uncertainties that can cause actual results to differ

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot